What Happened?
Waltham, MA-based Syndax Appointed Arlene Morris as Chief Executive Officer
About the Company
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.
About the Person
Ms. Arlene M. Morris served as the Chief Executive Officer of Syndax Pharmaceuticals, Inc. since March 2012 and its President since September 2013. Ms. Morris served as a Consultant of Affymax Inc. from February 1, 2011 to September 30, 2011. She served as the Chief Executive Officer of Affymax, Inc. from June 2003 to February 1, 2011 and its President from June 2003 to April 2010. Ms. Morris served as the Chief Executive Officer and President of Clearview Projects from 2001 to 2003. She served as a Senior Vice President of Business Development at Corixa.
Info Source
Press Release
Short Profile